Medical Developments International (ASX:MVP) has announced the approval of pain reliever PENTHROX (methoxyflurane) in Thailand.
The marketing authorisation, which was issued by the Thailand Food and Drug Administration, is for PENTHROX to be used for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
According to MVP chairman David Williams, “This is an important approval as Thailand is a key market for PENTHROX throughout the Asian Region. It is the first approval we have obtained with our partners Daiichi Sankyo who are also our partners in China and Vietnam.
"We expect the granting of this Marketing Authorisation will have positive ramifications for the rest of this region and we hope this approval is a catalyst for a number of other country approvals in Asia,” added Mr Williams.